Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synovitis Granules
- Development stage
- Phase 4
- Lead developer
- Shijiazhuang Third Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Synovitis Granules is an experimental multi-ingredient pharmaceutical drug, likely a Traditional Chinese Medicine (TCM) formulation, being investigated for the treatment of knee osteoarthritis. It is believed to exert its therapeutic effects by inhibiting inflammation and bone cell fibrosis, potentially through the suppression of the SDF-1/CXCR4 signaling pathway, leading to reduced expression of SDF-1, CXCR4, MMP-9, and MMP-13. This mechanism suggests anti-inflammatory and cartilage-protective properties.
Beyond the preview
Go deeper on Synovitis Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synovitis Granules.